Consequently, to identify a putative AML with BCR::ABL, it seems necessary not only (1) to verify that BCR::ABL1 is the first event of the multi-step process (using clonogenic assay and single-cell analysis), (2) to highlight the presence of typical AML abnormalities in addition to BCR::ABL1 (using NGS and RNA-Seq), but also (3) to eliminate “specific” BC-CML mutations, such as ABL1 TKD mutations. This evidence concerns the gene ABL1 and breast cancer.